Naresh Mahajan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Naresh Mahajan has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Akbar Bhat
Department of Human Genetics, Guru Nanak Dev University, Amritsar, India
1 shared publication- Arun Kumar
Department of Developmental Biology and Genetics, Indian Institute of Science, Bangalore, India
1 shared publication Gursatej Gandhi
Department of Human Genetics, Guru Nanak Dev University, Amritsar, India
1 shared publication- K. N. Lokesh
Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bangalore, India
1 shared publication - Lakkavalli Krishnappa Rajeev
Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, India
1 shared publication - Radha Mishra
Department of Developmental Biology and Genetics, Indian Institute of Science, Bangalore, India
1 shared publication
Latest Publications
- 6 June 2025
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 17 (3) , 631-643
Whole exome sequencing of lung cancer in Indian patients reveals driver genes and novel mutations with therapeutic potential
Lung cancer remains a leading cause of cancer mortality in India, yet its genomic landscape remains understudied. To address this gap, we performed whole-exome sequencing (WES) on tumor and matched blood samples from 47 lung cancer patients [adenocarcinoma (ADC): 30; squamous cell carcinoma (SqCC): 10; and small cell lung cancer (SCLC): 7] to comprehensively analyze somatic mutations across all protein-coding genes. Our analysis revealed novel and recurrent alterations, with MUC4 being the most recurrently mutated gene, and TP53 emerging as the most frequently mutated across subtypes. Shared mutations included MUC4, MUC16, TP53, KMT2C, CDC27, and UBXN11, the latter not previously associated with lung cancer. ADC exhibited the highest mutational diversity, particularly in RTK/MAPK pathway genes (EGFR, KRAS, BRAF, ERBB2, PIK3CG). Notably, EGFR mutations were identified in 26.7% of ADC cases, including exon 19 deletions (5 cases), exon 21 missense mutations (2 cases), and exon 20 insertions (3 cases) and a novel EGFR exon 20 duplication (p.Ser768_Asp770dup). SqCC showed frequent mutations in KMT2D, ARID2, and FBXW7, suggesting a role for epigenetic dysregulation. One SqCC case harbored a rare EGFR p.Glu866Gly mutation. SCLC was enriched for TP53 (43%) and RB1 (14%) mutations, along with alterations in FAT4 and LRP1B. Importantly, therapeutically actionable mutations were identified in 91.5% patients, including those with NCCN-recommended (25.5%) and FDA-approved off-label drug targets (68.1%). These findings underscore the value of WES in uncovering clinically relevant mutations and support the integration of genomic profiling into precision oncology strategies for Indian lung cancer patients.
- 6 June 2025
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 17 (3) , 631-643
Whole exome sequencing of lung cancer in Indian patients reveals driver genes and novel mutations with therapeutic potential
Lung cancer remains a leading cause of cancer mortality in India, yet its genomic landscape remains understudied. To address this gap, we performed whole-exome sequencing (WES) on tumor and matched blood samples from 47 lung cancer patients [adenocarcinoma (ADC): 30; squamous cell carcinoma (SqCC): 10; and small cell lung cancer (SCLC): 7] to comprehensively analyze somatic mutations across all protein-coding genes. Our analysis revealed novel and recurrent alterations, with MUC4 being the most recurrently mutated gene, and TP53 emerging as the most frequently mutated across subtypes. Shared mutations included MUC4, MUC16, TP53, KMT2C, CDC27, and UBXN11, the latter not previously associated with lung cancer. ADC exhibited the highest mutational diversity, particularly in RTK/MAPK pathway genes (EGFR, KRAS, BRAF, ERBB2, PIK3CG). Notably, EGFR mutations were identified in 26.7% of ADC cases, including exon 19 deletions (5 cases), exon 21 missense mutations (2 cases), and exon 20 insertions (3 cases) and a novel EGFR exon 20 duplication (p.Ser768_Asp770dup). SqCC showed frequent mutations in KMT2D, ARID2, and FBXW7, suggesting a role for epigenetic dysregulation. One SqCC case harbored a rare EGFR p.Glu866Gly mutation. SCLC was enriched for TP53 (43%) and RB1 (14%) mutations, along with alterations in FAT4 and LRP1B. Importantly, therapeutically actionable mutations were identified in 91.5% patients, including those with NCCN-recommended (25.5%) and FDA-approved off-label drug targets (68.1%). These findings underscore the value of WES in uncovering clinically relevant mutations and support the integration of genomic profiling into precision oncology strategies for Indian lung cancer patients.
- Open Access
- 1 January 2014
- Published by Springer Nature in Molecular Cytogenetics
- Vol. 7 (Suppl 1) , P49
Genetic damage biomarkers in buccal epithelial cells of healthy individuals staying near three mobile phone base stations
- 1 January 2014
- Published by Springer Nature in Molecular Cytogenetics
- Vol. 7 (Suppl 1) , P49
Open AccessGenetic damage biomarkers in buccal epithelial cells of healthy individuals staying near three mobile phone base stations